Fig. 4.

Antinociceptive activity of CYM51010. (A and B) Mice were s.c. administered with CYM51010 (51050) or morphine (Mor; 1, 3, 6, or 10 mg/kg body weight). (C) Mice were i.p. administered with vehicle, NTX, or NTB at the indicated doses 30 min before Mor (10 mg/kg s.c.) or CYM51010 (10 mg/kg s.c.) administration. (D) Mice were i.t. administered with CYM51010 (3, 10, or 30 nmol). E represents AUC calculated from data in D. (F) Mice were i.t. administered with vehicle, control IgG (anti-Flag IgG; 1 μg), or μ-δ mAb (1 μg) 30 min before CYM51010 (30 nmol i.t.) administration. (G) Mice were administered with either Mor or CYM51010 (10 mg/kg s.c.) one time daily for 8 d, and antinociception was measured daily. (A–G) Antinociceptive activity was measured as described in Materials and Methods. Results are mean ± SE (n = 3–18 mice per group). *P < 0.05; **P < 0.01 as determined by ANOVA followed by multiple comparison test (Student Newman–Keuls test) or unpaired t test. n.s., not significant.